Back to School: How biopharma can reboot drug development. Access exclusive analysis here

LE-SN38: Phase I data

In a U.S. Phase I trial in 68 patients LE-SN38 was well tolerated

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE